Cholangiocarcinoma as an Indication for Liver Transplantation in the Era of Transplant Oncology.
Enrico GringeriMartina GambatoGonzalo SapisochinTommy IvanicsErica Nicola LynchClaudia MescoliPatrizia BurraUmberto CilloFrancesco Paolo RussoPublished in: Journal of clinical medicine (2020)
Cholangiocarcinoma (CCA) arises from the biliary tract epithelium and accounts for 10-15% of all hepatobiliary malignancies. Depending on anatomic location, CCA is classified as intrahepatic (iCCA), perihilar (pCCA) and distal (dCCA). The best treatment option for pCCA is liver resection and when a radical oncological surgery is obtained, 5-year survival rate are around 20-40%. In unresectable patients, following a specific protocol, liver transplantation (LT) for pCCA showed excellent long-term disease-free survival rates. Fewer data are available for iCCA in LT setting. Nevertheless, patients with very early unresectable iCCA appear to achieve excellent outcomes after LT. This review aims to evaluate existing evidence to define the current role of LT in the management of patients with CCA.
Keyphrases
- free survival
- minimally invasive
- end stage renal disease
- newly diagnosed
- ejection fraction
- locally advanced
- chronic kidney disease
- randomized controlled trial
- palliative care
- rectal cancer
- liver metastases
- prognostic factors
- coronary artery bypass
- squamous cell carcinoma
- radiation therapy
- machine learning
- acute coronary syndrome
- atrial fibrillation
- deep learning
- data analysis